AgeLess Therapeutics

AgeLess Therapeutics is a clinical-stage biotechnology company focused on developing regenerative therapies for urological and sexual health conditions. The company's lead program, AgeLess-01, is a patented combination therapy of verapamil and dexamethasone delivered via intralesional injection for the treatment of Peyronie's Disease. By targeting the underlying fibrotic process, AgeLess Therapeutics aims to provide non-surgical alternatives for patients suffering from penile curvature and associated dysfunction. The company is headquartered in Florida and has conducted Phase 2 clinical trials to evaluate the safety and efficacy of its localized treatment approach. Their mission is to improve patient outcomes in sexual medicine through innovative pharmacological interventions.